Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Sees Significant Decrease in Short Interest

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) was the target of a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 43,800 shares, a decrease of 7.2% from the November 30th total of 47,200 shares. Based on an average daily trading volume, of 43,700 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.6% of the company’s stock are short sold.

Institutional Trading of Hepion Pharmaceuticals

A hedge fund recently bought a new stake in Hepion Pharmaceuticals stock. Anson Funds Management LP bought a new stake in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned about 3.33% of Hepion Pharmaceuticals as of its most recent SEC filing. 17.24% of the stock is owned by institutional investors and hedge funds.

Hepion Pharmaceuticals Stock Down 3.7 %

Hepion Pharmaceuticals stock traded down $0.02 during midday trading on Monday, hitting $0.44. 45,633 shares of the stock were exchanged, compared to its average volume of 79,167. Hepion Pharmaceuticals has a 52-week low of $0.44 and a 52-week high of $3.49. The business’s 50-day moving average price is $0.62 and its 200-day moving average price is $0.74. The stock has a market capitalization of $3.08 million, a price-to-earnings ratio of -0.10 and a beta of 1.63.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.